16 results
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
16 Aug 12
Bio-Path Holdings Reports Second Quarter 2012
12:00am
the capacity of its drug supply chain. The necessity for increased drug supply is based on the experience with treating patients in Cohort 3 … of drug from the new supply chain was delivered to the Company in July of 2012.
Bio-Path’s common stock began trading on the quality-controlled OTCQX
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
26 Jul 12
Bio-Path Holdings Begins Enrollment in Fourth Cohort of
12:00am
of the latest batch of drug product from our new supply chain and the opening of the fourth cohort of our clinical trial are important steps … for the Company,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path. “Establishing the new, higher capacity supply chain for our drug
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
18 May 12
Bio-Path Holdings Reports First Quarter 2012
12:00am
the capacity of its drug supply chain. Substantially increased supplies of the drug candidate Liposomal Grb-2 should be available in June of 2012 … have dramatically increased the capacity of our supply chain.”
About Bio-Path’s Delivery Technology
Bio-Path’s drug delivery technology involves
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
30 May 12
Other Events
12:00am
the capacity of our supply chain. We expect new supplies to become available to continue treatment of patients in June. The fourth cohort is ready
424B3
w0wpdf 8s03c
15 May 12
Prospectus supplement
12:00am
424B3
160fc e30u43
15 Aug 12
Prospectus supplement
12:00am
424B3
os95vmr fkvcx
15 Nov 12
Prospectus supplement
12:00am
- Prev
- 1
- Next